Pharmaceutical Preparations
Standard Industrial Classification: SIC 2834
Industry Insider Sentiment Analysis
The Pharmaceutical Preparations sector (SIC 2834) acts as a critical barometer for broader economic health. Our real-time monitoring reveals total transactions. Monitoring "cluster buying" is one of the most reliable leading indicators for future sector performance. By analyzing aggregate data across this specific Standard Industrial Classification, investors can filter out individual company volatility and identify high-conviction trends. When multiple directors and officers within the same industry move capital simultaneously, it often signals an upcoming sector-wide revaluation or a fundamental shift in supply chain dynamics that has yet to be recognized by the broader public market.
| Filing Date | Trade Date | Ticker | Company | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-02-04 05:30 | 2026-02-03 | TVTX | Travere Therapeutics, Inc. | Inrig Jula | Officer | SELL | $32.12 | 6,956 | $223,427 | 107,485 |
| 2026-02-04 05:30 | 2026-02-03 | TVTX | Travere Therapeutics, Inc. | Calvin Sandra | Officer | SELL | $32.12 | 4,333 | $139,176 | 49,080 |
| 2026-02-04 05:30 | 2026-02-03 | TVTX | Travere Therapeutics, Inc. | Heerma Peter | Officer | SELL | $32.12 | 7,310 | $234,797 | 131,823 |
| 2026-02-04 05:30 | 2026-02-03 | TVTX | Travere Therapeutics, Inc. | Dube Eric M | Director, Officer | SELL | $32.28 | 100,087 | $3,230,318 | 432,886 |
| 2026-02-04 05:30 | 2026-02-03 | TVTX | Travere Therapeutics, Inc. | ROTE WILLIAM E. | Officer | SELL | $32.87 | 12,446 | $409,100 | 109,087 |
| 2026-02-04 02:24 | 2026-02-02 | PCRX | Pacira BioSciences, Inc. | RIKER LAUREN | Officer | SELL | $20.81 | 4,000 | $83,240 | 52,313 |
| 2026-02-03 20:35 | 2026-02-02 | SER | Serina Therapeutics, Inc. | Moreadith Randall | Officer | OPT+S | $3.03 | 6,500 | $19,680 | 0 |
| 2026-02-04 02:24 | 2026-02-02 | PCRX | Pacira BioSciences, Inc. | WILLIAMS KRISTEN | Officer | SELL | $20.53 | 13,137 | $269,703 | 131,303 |
| 2026-02-04 05:30 | 2026-02-03 | TVTX | Travere Therapeutics, Inc. | REED ELIZABETH E | Officer | SELL | $32.12 | 7,175 | $230,461 | 108,205 |
| 2026-02-04 00:30 | 2026-02-02 | ZBIO | Zenas BioPharma, Inc. | MOULDER LEON O JR | Director, Officer | BUY | $17.96 | 57,000 | $1,023,720 | 423,155 |
| 2026-02-04 00:26 | 2026-02-02 | BIOA | BioAge Labs, Inc. | RUBIN PAUL D | Officer | OPT+S | $18.75 | 7,433 | $139,369 | 0 |
| 2026-02-04 00:31 | 2026-02-03 | UTHR | UNITED THERAPEUTICS Corp | MALCOLM JAN | Director | SELL | $474.23 | 50 | $23,712 | 270 |
| 2026-02-04 00:31 | 2026-02-02 | UTHR | UNITED THERAPEUTICS Corp | BENKOWITZ MICHAEL | Officer | OPT+S | $470.95 | 22,500 | $10,596,429 | 0 |
| 2026-02-03 04:51 | 2026-01-30 | IONS | IONIS PHARMACEUTICALS INC | Birchler Brian | Officer | SELL | $83.03 | 6,179 | $513,048 | 66,247 |
| 2026-02-03 00:30 | 2026-01-29 | NUVL | Nuvalent, Inc. | Noci Darlene | Officer | OPT+S | $102.08 | 5,500 | $561,422 | 58,117 |
| 2026-02-03 02:59 | 2026-02-02 | ABEO | Abeona Therapeutics Inc. | Wuchterl Donald A. | Director | SELL | $5.09 | 14,814 | $75,412 | 167,935 |
| 2026-02-03 04:52 | 2026-01-30 | IONS | IONIS PHARMACEUTICALS INC | Schneider Eugene | Officer | SELL | $83.45 | 6,179 | $515,630 | 69,702 |
| 2026-02-03 00:30 | 2026-02-02 | ABEO | Abeona Therapeutics Inc. | Alland Leila | Director | SELL | $5.09 | 18,065 | $91,962 | 173,614 |
| 2026-02-03 01:10 | 2026-01-29 | CLNN | Clene Inc. | Ugwumba Chidozie | 10% owner | SELL | $4.23 | 24,770 | $104,861 | 555,559 |
| 2026-02-03 04:51 | 2026-01-30 | IONS | IONIS PHARMACEUTICALS INC | Baroldi Joseph | Officer | SELL | $82.96 | 5,296 | $439,364 | 45,413 |
| 2026-02-03 00:59 | 2026-01-30 | RPRX | Royalty Pharma plc | Urist Marshall | Officer | SELL | $41.09 | 20,000 | $821,810 | 0 |
| 2026-02-03 04:52 | 2026-01-30 | IONS | IONIS PHARMACEUTICALS INC | Swayze Eric | Officer | SELL | $82.93 | 6,179 | $512,446 | 47,747 |
| 2026-02-03 00:08 | 2026-01-30 | APRE | Clear Creek Independent School District | Gilad Oren | Director, Officer | BUY | $0.89 | 28,100 | $25,009 | 373,720 |
| 2026-02-03 00:05 | 2026-01-30 | APRE | Clear Creek Independent School District | Hamill John P. | Officer | BUY | $0.89 | 5,700 | $5,073 | 33,433 |
| 2026-02-03 02:55 | 2026-02-02 | ABEO | Abeona Therapeutics Inc. | Crombez Eric | Director | SELL | $5.09 | 16,284 | $82,895 | 63,456 |
| 2026-02-03 02:11 | 2026-02-02 | XERS | Xeris Biopharma Holdings, Inc. | Hecht Beth | Officer | SELL | $7.45 | 16,667 | $124,147 | 1,243,174 |
| 2026-02-03 04:51 | 2026-01-30 | IONS | IONIS PHARMACEUTICALS INC | O'NEIL PATRICK R. | Officer | SELL | $83.53 | 6,179 | $516,153 | 71,983 |
| 2026-02-03 04:51 | 2026-01-30 | IONS | IONIS PHARMACEUTICALS INC | Monia Brett P | Director, Officer | SELL | $82.72 | 62,970 | $5,208,979 | 283,927 |
| 2026-02-03 04:52 | 2026-02-02 | ALKS | Alkermes plc. | Hopkinson Craig C. | Officer | OPT+S | $33.93 | 9,000 | $305,384 | 57,740 |
| 2026-02-03 04:48 | 2026-02-02 | ALKS | Alkermes plc. | Cooke Shane | Director | OPT+S | $34.57 | 61,200 | $2,115,672 | 103,744 |
| 2026-02-03 01:19 | 2026-01-30 | ZVRA | ZEVRA THERAPEUTICS, INC. | Schafer Joshua | Officer | OPT+S | $8.83 | 3,375 | $29,800 | 37,444 |
| 2026-02-03 01:19 | 2026-01-30 | ZVRA | ZEVRA THERAPEUTICS, INC. | Quartel Adrian W | Officer | OPT+S | $8.83 | 4,533 | $40,036 | 9,723 |
| 2026-02-03 01:19 | 2026-01-30 | ZVRA | ZEVRA THERAPEUTICS, INC. | Thompson Rahsaan | Officer | OPT+S | $8.83 | 4,080 | $36,010 | 49,919 |
| 2026-02-03 01:19 | 2026-01-30 | ZVRA | ZEVRA THERAPEUTICS, INC. | Sangiovanni Timothy J. | Officer | OPT+S | $8.82 | 1,750 | $15,442 | 20,924 |
| 2026-02-03 01:18 | 2026-02-02 | ZVRA | ZEVRA THERAPEUTICS, INC. | McFarlane Neil F. | Director, Officer | OPT+S | $9.38 | 91,000 | $853,425 | 364,350 |
| 2026-02-03 00:30 | 2026-02-02 | ABEO | Abeona Therapeutics Inc. | Alvino Mark | Director | SELL | $5.09 | 2,000 | $10,181 | 84,065 |
| 2026-02-03 02:30 | 2026-02-02 | AXSM | Axsome Therapeutics, Inc. | TABUTEAU HERRIOT | Director, Officer, 10% owner | OPT+S | $185.60 | 32,410 | $6,015,296 | 7,229 |
| 2026-02-03 04:51 | 2026-01-30 | IONS | IONIS PHARMACEUTICALS INC | HOUGEN ELIZABETH L | Officer | SELL | $83.24 | 6,988 | $581,702 | 132,881 |
| 2026-02-03 04:51 | 2026-01-30 | IONS | IONIS PHARMACEUTICALS INC | BENNETT C FRANK | Officer | SELL | $82.95 | 5,885 | $488,141 | 100,293 |
| 2026-02-03 00:15 | 2026-01-29 | PAHC | PHIBRO ANIMAL HEALTH CORP | BENDHEIM JACK | Director, Officer, 10% owner | SELL | $40.11 | 13,465 | $540,037 | 31,980 |
| 2026-02-03 00:40 | 2026-02-02 | CYTK | CYTOKINETICS INC | Callos Andrew | Officer | OPT+S | $62.10 | 886 | $55,021 | 50,440 |
| 2026-01-31 00:52 | 2026-01-28 | CTNM | Contineum Therapeutics, Inc. | Watkins Tim | Officer | OPT+S | $14.18 | 3,611 | $51,188 | 0 |
| 2026-01-31 04:50 | 2026-01-28 | MPLT | MapLight Therapeutics, Inc. | Malenka Robert C. | Director | SELL | $18.49 | 34,398 | $635,857 | 365,273 |
| 2026-01-31 04:39 | 2026-01-30 | NRIX | Nurix Therapeutics, Inc. | van Houte Hans | Officer | OPT+S | $16.60 | 3,661 | $60,766 | 45,427 |
| 2026-01-31 04:38 | 2026-01-30 | NRIX | Nurix Therapeutics, Inc. | Ring Christine | Officer | OPT+S | $16.60 | 4,421 | $73,381 | 57,010 |
| 2026-01-31 04:36 | 2026-01-30 | NRIX | Nurix Therapeutics, Inc. | Hansen Gwenn | Officer | OPT+S | $16.60 | 4,895 | $81,249 | 83,672 |
| 2026-01-30 00:40 | 2026-01-27 | NAMS | NewAmsterdam Pharma Co N.V. | Kooij Louise Frederika | Officer | OPT+S | $32.25 | 72,428 | $2,335,861 | 24,353 |
| 2026-01-29 16:58 | 2026-01-28 | ANIX | Anixa Biosciences Inc. | Baskies Arnold M | Director | BUY | $3.04 | 10,000 | $30,400 | 135,000 |
| 2026-01-30 00:16 | 2026-01-27 | SLGL | Sol-Gel Technologies Ltd. | Opaleye Management Inc. | 10% owner | BUY | $57.05 | 100 | $5,705 | 449,944 |
| 2026-01-30 00:57 | 2026-01-28 | KPTI | Karyopharm Therapeutics Inc. | Abate Kristin | Officer | SELL | $7.03 | 50 | $352 | 22,622 |
Sector-Wide Insider Alpha
Analyzing insider movements across the Pharmaceutical Preparations sector provides a macro-view of executive conviction. When multiple leaders in different companies within the same SIC code (2834) simultaneously buy shares, it often indicates an industry-wide undervaluation or a positive shift in market cycles.
SEC Filings in Pharmaceutical Preparations
Every transaction in the Pharmaceutical Preparations industry is reported via Form 4 disclosures. By filtering these filings by industry, investors can detect institutional-scale sentiment shifts before they are reflected in broader market indices, following the capital flow of those with intimate industry knowledge.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.